⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9246448 | 1.00 | — | — | |
| SCHEMBL16208282 | 1.00 | — | — | |
| SCHEMBL96725 | 1.00 | — | — | |
| SCHEMBL6473918 | 0.82 | — | — | |
| SCHEMBL28801785 | 0.82 | — | — | |
| SCHEMBL6479837 | 0.82 | — | — | |
| SCHEMBL1325417 | 0.82 | — | — | |
| SCHEMBL23083 | 0.82 | — | — | |
| SCHEMBL23084 | 0.82 | — | — | |
| SCHEMBL1325430 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0337333-B1 | PROCESS FOR TREATING USED AND SOILED ELECTRONICAL OR ELECTROMECHANICAL PARTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1993-08-18 | — | — | EP | claimed |
| US-7285546-B2 | Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents | STRAGEN PHARMA S.A. (CH) | 2007-10-23 | — | — | US | disclosed |
| EP-1328527-B1 | CEPHALOTAXANES, THEIR METHOD OF PREPARATION AND THEIR USE IN TREATMENT OF CANCERS, LEUKEMIAS, PARASITES INCLUDING THOSE RESISTANT TO USUAL CHEMOTHERAPEUTIC AGENTS AND AS REVERSAL AGENTS | STRAGEN PHARMA SA (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006064-A1 | Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents | IVAX International GmbH (CH) | 2004-01-08 | — | — | US | disclosed |
| US-6579869-B1 | Hydrolysis, esterification | ONCOPHARM CORPORATION | 2003-06-17 | — | — | US | disclosed |